1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Evolva Holding SA
  6. Summary
    EVE   CH0021218067

EVOLVA HOLDING SA

(EVE)
  Report
Delayed Swiss Exchange  -  04:16 2022-08-11 am EDT
0.0970 CHF   +2.11%
07/26Evolva To Hit FY22 Revenue Growth Target Following First-half Surge
MT
07/26Evolva with strong business momentum in 1H 2022, announcing targets of mid-term plan
EQ
05/24Swiss Biotech Evolva Raises $7 Million Via Private Placement
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
08/05/2022 08/08/2022 08/09/2022 08/10/2022 08/11/2022 Date
0.093(c) 0.0928(c) 0.0951(c) 0.095(c) 0.097 Last
430 183 1 579 216 751 979 819 515 151 113 Volume
-3.13% -0.22% +2.48% -0.11% +2.11% Change
More quotes
Estimated financial data (e)
Sales 2022 15,0 M 16,0 M 16,0 M
Net income 2022 -22,0 M -23,4 M -23,4 M
Net cash position 2022 11,5 M 12,3 M 12,3 M
P/E ratio 2022 -4,75x
Yield 2022 -
Sales 2023 24,0 M 25,5 M 25,5 M
Net income 2023 -17,0 M -18,1 M -18,1 M
Net cash position 2023 8,00 M 8,50 M 8,50 M
P/E ratio 2023 -9,50x
Yield 2023 -
Capitalization 103 M 109 M 109 M
EV / Sales 2022 6,08x
EV / Sales 2023 3,95x
Nbr of Employees 68
Free-Float 90,2%
More Financials
Company
Evolva Holding SA (Evolva) is a Switzerland-based biotechnology company reseaching, developing and commerzializing nature-based ingrendients. The activity of the Company is divided into two segments: technololgy platforms - combines biology with technology to produce nature-based ingredients; technology servises- provides tailored services to clients across industries. The Company is focused on developing and... 
More about the company
Ratings of Evolva Holding SA
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about EVOLVA HOLDING SA
07/26Evolva To Hit FY22 Revenue Growth Target Following First-half Surge
MT
07/26Evolva with strong business momentum in 1H 2022, announcing targets of mid-term plan
EQ
05/24Swiss Biotech Evolva Raises $7 Million Via Private Placement
MT
05/24Evolva successfully placed shares from authorized capital, raising CHF 6.3 million
EQ
05/24Evolva Holding SA announced that it has received CHF 6.3226 million in funding
CI
05/19EVOLVA BUSINESS UPDATE : On track to reach 2022 guidance
EQ
05/17Evolva signs distribution agreement for its Veri-teTM Resveratrol for dietary supplemen..
AQ
05/12Evolva signs distribution agreement for its Veri-teTM Resveratrol for dietary supplemen..
EQ
05/12Evolva Signs Distribution Agreement with Tovani Benzaquen Ingredients for Its Veri-Tetm..
CI
05/05Evolva shareholders approve all proposed resolutions at the Annual General Meeting 2022
EQ
05/05Evolva Holding SA Announces Management Appointments
CI
04/20Evolva Hits 20% Of FY21 Revenue With Production Milestone
MT
04/20Evolva achieves important product-related milestones with global customer, triggering r..
EQ
04/07Evolva's AGM postponed to May 5, 2022 / agenda remains unchanged
EQ
03/22Evolva Plans To Increase Conditional, Authorized Share Capital
MT
More news
News in other languages on EVOLVA HOLDING SA
07/26Evolva atteindra l'objectif de croissance du chiffre d'affaires de l'exercice 22 après ..
07/26Evolva en avance sur ses objectifs au premier semestre
07/26Evolva auf Kurs für angestrebten Jahresumsatz von 15 Mio Franken
05/24Evolva lève plus de 6 millions avec une augmentation de capital
05/24Evolva nimmt bei Aktienplatzierung gut 6 Millionen Franken ein
More news
Analyst Recommendations on EVOLVA HOLDING SA
More recommendations
Chart EVOLVA HOLDING SA
Duration : Period :
Evolva Holding SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOLVA HOLDING SA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,10 CHF
Average target price 0,18 CHF
Spread / Average Target 89,5%
EPS Revisions
Managers and Directors
Christian Wichert Chief Executive Officer
Beat In-Albon Chairman
Astrid Schäfer Head-Research & Development
Gerhard Lobmaier Chief Operating Officer
Nic Buergin Secretary, Head-Legal & Compliance
Sector and Competitors
1st jan.Capi. (M$)
EVOLVA HOLDING SA-29.03%109
MODERNA, INC.-31.38%68 174
LONZA GROUP AG-26.76%44 940
IQVIA HOLDINGS INC.-15.05%44 704
SEAGEN INC.13.62%32 396
ALNYLAM PHARMACEUTICALS, INC.36.81%27 846